Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15180046 | 0.84 | CA1 (0.50) | HTR2ACA1CA2CA12CA7 | |
| SCHEMBL25745801 | 0.82 | ACHE (0.41) | HTR2AHTR2CARCRHR1ALDH1A1 | |
| SCHEMBL22017132 | 0.82 | HTR2A (0.39) | HTR2AHTR2CCRHR1 | |
| SCHEMBL19871663 | 0.81 | HTR2A (0.38) | HTR2AHTR2CARMEN1KMT2A | |
| SCHEMBL5185794 | 0.80 | ALDH1A1 (0.48) | CA1CA2CA12CA7CA9 | |
| SCHEMBL16011478 | 0.80 | ERN1 (0.38) | HTR2AHTR2CEPHX2ALDH1A1 | |
| SCHEMBL25745865 | 0.79 | HTR2A (0.37) | HTR2AHTR2CCRHR1 | |
| SCHEMBL1041890 | 0.74 | ENPP3 (0.39) | HTR2AHTR2CARCA1CA2 | |
| SCHEMBL1042619 | 0.74 | CA1 (0.38) | HTR2AHTR2CARCA1CA2 | |
| SCHEMBL13067435 | 0.73 | ALDH1A1 (0.40) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| CN-105142603-B | Resorcinol compounds for dermatological use | 荷兰联合利华有限公司 | 2018-10-19 | — | — | CN | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | Unilever PLC, a company registered in England and Wales under company no. 41424 of (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| CN-105142603-A | Resorcinol compounds for dermatological use | UNILEVER NV | 2015-12-09 | — | — | CN | disclosed |
| WO-2014138471-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | AMPERE LIFE SCIENCES, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138471-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | AMPERE LIFE SCIENCES, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | HTR2A 4010/4885HTR2C 4586/4885AR 2469/4885 |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | HTR2A 4010/4885HTR2C 4586/4885AR 2469/4885 |
| US-10470986-B2 | Resorcinol compounds for dermatological use | NQO1, RBP4, KEAP1 | HTR2A 4010/4885HTR2C 4586/4885AR 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.